How were 12942 (NTB.V)'s earnings last quarter?

12942 (NTB.V) (CVE:NTB) issued its earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million.

Is 12942 (NTB.V) a good dividend stock?

12942 (NTB.V) (CVE:NTB) pays an annual dividend of C$1.52 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of 12942 (NTB.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 12942 (NTB.V) investors own include ACADIA Pharmaceuticals (ACAD) , Adverum Biotechnologies (ADVM) , Aimmune Therapeutics (AIMT) , ANI Pharmaceuticals (ANIP) , AxoGen (AXGN) , Biohaven (BHVN) , bluebird bio (BLUE) , Blueprint Medicines (BPMC) , Calithera Biosciences (CALA) and Codexis (CDXS) .

How do I buy shares of 12942 (NTB.V)?

Shares of NTB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

CVE:NTB

12942 (NTB.V) (NTB) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NTB Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 31,049 shs
Average Volume: 315,395 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get 12942 (NTB.V) alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About 12942 (NTB.V)

Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company’s products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

NTB Stock News Headlines

February 9, 2024 | wsj.com

Bank of Butterfield Ltd.

November 23, 2023 | seekingalpha.com

NTB Dividend Yield Grade

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 19, 2023 | time.com

Ntb Coupons

February 19, 2023 | finance.yahoo.com

NYSE U.S. 100 Index (^NY)

See More Headlines

Receive NTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 12942 (NTB.V) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/15/2014
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Finance
Industry: Regional Banks
Sub-Industry: N/A
Current Symbol: CVE:NTB
CUSIP: N/A
CIK: N/A
Web: neptunekrilloil.com
Phone: +1-450-6872262
Fax: N/A
Employees: 1,134
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

John Moretz
Chairman of the Board
James Stuart Hamilton
President, Chief Executive Officer, Director
Mario Paradis
Chief Financial Officer
Michel Timperio
Senior Vice President of Sales - Global Sales
Pierre Lemieux Ph.D.
Chief Operating Officer of Acasti
Jean-Daniel Belanger
Corporate Secretary and Director - Corporate Affairs
Harlan W. Waksal M.D. (Age 61)
Director
Valier Boivin
Independent Director
Ronald Denis
Independent Director
Adrian Taylor Montgomery
Independent Director

Key Competitors

View All Competitors

NTB Stock Analysis - Frequently Asked Questions

How were 12942 (NTB.V)'s earnings last quarter?: 12942 (NTB.V) (CVE:NTB) issued its earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million.
Is 12942 (NTB.V) a good dividend stock?: 12942 (NTB.V) (CVE:NTB) pays an annual dividend of C$1.52 per share and currently has a dividend yield of 0.00%.
What other stocks do shareholders of 12942 (NTB.V) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 12942 (NTB.V) investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).
How do I buy shares of 12942 (NTB.V)?: Shares of NTB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:NTB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

12942 (NTB.V) (NTB) Stock Price, News & Analysis

About 12942 (NTB.V)

NTB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NTB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info